| Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions V Goede, K Fischer, R Busch, A Engelke, B Eichhorst, CM Wendtner, ... New England Journal of Medicine 370 (12), 1101-1110, 2014 | 1920 | 2014 |
| Venetoclax and obinutuzumab in patients with CLL and coexisting conditions K Fischer, O Al-Sawaf, J Bahlo, AM Fink, M Tandon, M Dixon, S Robrecht, ... New England Journal of Medicine 380 (23), 2225-2236, 2019 | 878 | 2019 |
| Obinutuzumab for the first-line treatment of follicular lymphoma R Marcus, A Davies, K Ando, W Klapper, S Opat, C Owen, E Phillips, ... New England Journal of Medicine 377 (14), 1331-1344, 2017 | 741 | 2017 |
| Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial S Horwitz, OA O'Connor, B Pro, T Illidge, M Fanale, R Advani, NL Bartlett, ... The Lancet 393 (10168), 229-240, 2019 | 694 | 2019 |
| Hemicraniectomy in older patients with extensive middle-cerebral-artery stroke E Jüttler, A Unterberg, J Woitzik, J Bösel, H Amiri, OW Sakowitz, ... New England Journal of Medicine 370 (12), 1091-1100, 2014 | 665 | 2014 |
| Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial F Morschhauser, H Tilly, A Chaidos, P McKay, T Phillips, S Assouline, ... The Lancet Oncology 21 (11), 1433-1442, 2020 | 416 | 2020 |
| Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma R Kridel, B Meissner, S Rogic, M Boyle, A Telenius, B Woolcock, ... Blood, The Journal of the American Society of Hematology 119 (9), 1963-1971, 2012 | 412 | 2012 |
| A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study CS Tam, S Opat, S D'Sa, W Jurczak, HP Lee, G Cull, RG Owen, P Marlton, ... Blood, The Journal of the American Society of Hematology 136 (18), 2038-2050, 2020 | 380 | 2020 |
| Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL CS Tam, J Trotman, S Opat, JA Burger, G Cull, D Gottlieb, R Harrup, ... Blood, The Journal of the American Society of Hematology 134 (11), 851-859, 2019 | 346 | 2019 |
| Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open … O Al-Sawaf, C Zhang, M Tandon, A Sinha, AM Fink, S Robrecht, ... The Lancet Oncology 21 (9), 1188-1200, 2020 | 308 | 2020 |
| Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II … WG Wierda, JN Allan, T Siddiqi, TJ Kipps, S Opat, A Tedeschi, XC Badoux, ... Journal of Clinical Oncology 39 (34), 3853, 2021 | 164 | 2021 |
| A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma CY Cheah, KE Herbert, K O'rourke, GA Kennedy, A George, PL Fedele, ... British journal of cancer 111 (6), 1072-1079, 2014 | 152 | 2014 |
| The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia A Catalano, MA Dawson, K Somana, S Opat, A Schwarer, LJ Campbell, ... Blood, The Journal of the American Society of Hematology 110 (12), 4073-4076, 2007 | 149 | 2007 |
| Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial CS Tam, JR Brown, BS Kahl, P Ghia, K Giannopoulos, W Jurczak, ... The Lancet Oncology 23 (8), 1031-1043, 2022 | 147 | 2022 |
| The BTK inhibitor, Bgb-3111, is safe, tolerable, and highly active in patients with relapsed/refractory B-cell malignancies: initial report of a phase 1 first-in-human trial C Tam, AP Grigg, S Opat, M Ku, M Gilbertson, MA Anderson, JF Seymour, ... Blood 126 (23), 832, 2015 | 144 | 2015 |
| The recognition of HLA-B27 by human CD4+ T lymphocytes LH Boyle, JC Goodall, SS Opat, JS Gaston The Journal of Immunology 167 (5), 2619-2624, 2001 | 139 | 2001 |
| ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura J Shortt, DH Oh, SS Opat New England Journal of Medicine 368 (1), 90-92, 2013 | 135 | 2013 |
| Venetoclax and obinutuzumab in chronic lymphocytic leukemia K Fischer, O Al-Sawaf, AM Fink, M Dixon, J Bahlo, S Warburton, TJ Kipps, ... Blood, The Journal of the American Society of Hematology 129 (19), 2702-2705, 2017 | 134 | 2017 |
| Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort CS Tam, JN Allan, T Siddiqi, TJ Kipps, R Jacobs, S Opat, PM Barr, ... Blood, The Journal of the American Society of Hematology 139 (22), 3278-3289, 2022 | 129 | 2022 |
| Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial J Trotman, SF Barrington, D Belada, M Meignan, R MacEwan, C Owen, ... The Lancet Oncology 19 (11), 1530-1542, 2018 | 129 | 2018 |
